Trial Design in the CDISC World
description
Transcript of Trial Design in the CDISC World
![Page 1: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/1.jpg)
Trial Design in the CDISC World
Albert Chau26 July 2011
1
![Page 2: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/2.jpg)
2
Agenda
How to construct Trial Design datasetso Relationships with other SDTM domains
Challenges for new userso Confusion of definitions/termso Granularity
Case study in oncology
![Page 3: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/3.jpg)
3
Trial Design Domains
Information about study designo No subject data
Describe the overall trial design and plan via data representation
![Page 4: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/4.jpg)
4
Trial Design Datasets
Trial Arms (TA) Trial Elements (TE) Trial Visits (TV) Trial Inclusion /Exclusion (TI) Trial Summary (TS)
Start thinking about this before you start the other SDTM datasets!
![Page 5: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/5.jpg)
5
Trial Summary (TS) Dataset
Summary of trial information No link to subject-level data in SDTM Common questions:
o What need to be included?o Why are we generating this?
![Page 6: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/6.jpg)
6
Trial Inclusion/Exclusion (TI)
Not subject-oriented Link to IE domain
o STUDYID, IECAT, IETESTCD, IETESTo Best to create TI first, before you tackle IE
Common questions:o How to truncate if >200 characters?o Protocol amendment: do we need to add to TI only the
changed criteria or all criteria?o Local amendment
![Page 7: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/7.jpg)
7
TA / TE / TV datasets
A data representation on the different epochs, arms and visit structure in the study
Where to start? Is there a systematic approach?
![Page 8: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/8.jpg)
8
Example 1 – Trial Design Schema
ScreenDrug A
Drug B
Follow-up
Follow-up
![Page 9: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/9.jpg)
9
Epoch
ScreenDrug A
Drug B
Follow-up
Follow-up
Screening Treatment Follow-upEPOCH
![Page 10: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/10.jpg)
10
Arm / Treatment Strategy
ScreenDrug A
Drug B
Follow-up
Follow-up
Screening Treatment Follow-up
AR
M(T
reat
men
t S
trate
gy)
1
2
![Page 11: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/11.jpg)
11
Arm / Treatment Strategy
ScreenDrug A
Drug B
Follow-up
Follow-up
Screening Treatment Follow-up
Study Cell
1
2
Screen
Screen
Drug A
Drug B
Follow-up
Follow-up
![Page 12: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/12.jpg)
12
Trial Design Matrix
Screening Treatment Follow-up
A
B
Screen
Screen
Drug A
Drug B
Follow-up
Follow-up
![Page 13: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/13.jpg)
13
TE (Trial Elements)
What are the elements?o Unique study cell values (=ELEMENT)
Screen
Drug A
Drug B
Follow-up
![Page 14: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/14.jpg)
14
TE (Trial Elements)
Assign an element code (ETCD) to each value, define the start of each element (TESTRL) and end of each element (TEENRL or TEDUR)
Screen
Drug A
Drug B
Follow-up
SCRN
A
B
FU
Informed Consent
First dose of drug A
First dose of drug B
1 week after last dose of drug
ETCD ELEMENT TESTRL
![Page 15: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/15.jpg)
15
Trial Arms (TA) Dataset
Go back to the Trial Design Matrix 1 study cell = 1 row of record in TA So in our example we expect 6 rows of record ARM / ARMCD
o = Treatment Strategy o Not necessarily the same as the actual drug
names/codes ETCD / ELEMENT
o Must match up with the values in TE
![Page 16: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/16.jpg)
16
TE -> SE (Subject Elements)
Shows the trial progress of each subjecto Whether a subject passes through each elemento Timing of each element
![Page 17: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/17.jpg)
17
Trial Visit (TV) Dataset
Describe the planned visits in a trial VISITNUM and TRSTRL is required ARMCD expected VISIT and VISITDY permissible 1 record per planned visit per arm
o A “visit” may span over several days (eg screening visit)
![Page 18: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/18.jpg)
18
TV -> SV (Subject Visits)
Shows the actual visits of each subjecto Compare against the scheduled/planned visits or
assessments in TVo Include unscheduled visits
Designation of VISITNUM becomes crucialo Whole number for planned visitso Decimals for unscheduled visits in SV – and slot into
right place
![Page 19: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/19.jpg)
19
Challenges in 1 oncology study
Leukemiao Drug X (Days 1-4) is the current standard of treatmento Drug A (Days 1-7) is the experimental treatment
Patients to receive:o Drug A+X vs Drug X (1 course of treatment)o If patients on drug X not responding, then option to
“crossover” to drug A+X (1 further course) Follow-up
o Responders: Efficacy follow-up (+ post-remission therapies where applicable)
o Non-responders and relapse: Survival follow-up
![Page 20: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/20.jpg)
20
Study schema
Screen
Drug A + X
Drug X
Drug A + X
Efficacy FU (q 1 months)
Survival FU (q 3 months)
![Page 21: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/21.jpg)
21
Question 1 – what are the epochs?
1 Treatment epoch or separate into 2? 1 Follow-up epoch or separate into 2?
Screen
Drug A + X
Drug X
Drug A + X
Efficacy FU (q 1 months)
Survival FU (q 3 months)
Screening Treatment Efficacy FU Survival FU
![Page 22: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/22.jpg)
22
Question 2 – How many arms?
For the patients on Drug X and then rollover to Drug A+X – should this considered as a separate “arm”?
Screen
Drug A + X
Drug X
Drug A + X
Efficacy FU (q 1 months)
Survival FU (q 3 months)
![Page 23: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/23.jpg)
23
Question 3 – Granularity of Elements
Do we model using “Treatment”+”Rest” or simply “Treatment” (which includes rest period)?
Length of “Rest” differs between patients Do we need to distinguish between “Treatment”
and “Rest”?
Treatment(Day 1 - 7)
Rest(Day 8 – ??)
Treatment(Day 1 - 37)
![Page 24: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/24.jpg)
24
Question 4 – Describing Trial Visits
How to number the visits, when you don’t know how many visits there are up-front?
Don’t have to be consecutive numbers Example:
o 1st course of treatment: Start with VISITNUM=11o Cross-over: Start with VISITNUM=51o Efficacy follow-up: Start with VISITNUM=201o Survival follow-up: Start with VISITNUM=501
![Page 25: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/25.jpg)
25
Question 5 – Varying Trial Visits
During Efficacy Follow-up, patients can receive “post-remission therapies”.
“Reset” follow-up clock from post-remission therapies
How to model Trial Elements and Visits?
![Page 26: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/26.jpg)
26
Question 5 – Varying Trial Visits
Suggestion:o Start with VISITNUM=201 for Efficacy Follow-upo Trial Element: Up to the next post-remission therapyo 1st Post-Remission therapy: VISITNUM=250o 2nd Post-Remission therapy: VISITNUM=300o etc
![Page 27: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/27.jpg)
27
Question 6 – Post-remission therapies
For post-remission therapies in efficacy follow-up, the choice is down to the treating physician
Can potentially be Drug X or any other therapies
Should we create Trial Elements for the different therapies?
![Page 28: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/28.jpg)
28
Question 7 – Randomised but not treated
Randomisation usually starts 1-2 days before start of treatment due to logistic reason
What is the start and end of “Screen” and “Drug A”/”Drug A+X” trial elements in TE?
How to capture these patients in SE? Should randomisation be a separate visit in
TV/SV?
![Page 29: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/29.jpg)
29
Question 8 – When is a visit no longer “planned”
Planned visits for lab assessments: Day 15, Day 21
A patient had lab taken on Day 17 and Day 22 instead
Should these be put into planned visits of Day 15 and Day 21, or unscheduled visits?
![Page 30: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/30.jpg)
30
Other challenges in oncology studies
Post-remission therapy will be given and patients will be followed up “according to institution’s standard treatment practice”
Dose escalation studies – how many arms? Legacy studies: Do we need to provide trial
design datasets?
![Page 31: Trial Design in the CDISC World](https://reader033.fdocuments.us/reader033/viewer/2022051317/568164ad550346895dd6b309/html5/thumbnails/31.jpg)
31
Summary
Construction of TA/TE/TVo Study Schema Epoch Arm Study Cellso Unique study cells = rows in TEo All study cells = rows in TAo If all arms have same visits, then 1 set of visits for all
arms. Otherwise 1 set of visits for each arm. Complex study designs
o Systematic approach will make life easiero Think at protocol/CRF design stage – don’t wait till the
endo Details vs ease of use